SCHEMBL3006535

SCHEMBL3006535

N#Cc1ccccc1N1C(=O)CN2C(=O)CCC21

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.36
AR P10275 1/20 0.35
P2RX7 Q99572 1/20 0.35
GRM5 P41594 1/20 0.34
GRM2 Q14416 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014074 0.78 MEN1 (0.41) NOTUMDDB1CRBN
SCHEMBL2997925 0.78 MEN1 (0.41) NOTUMDDB1CRBN
SCHEMBL3006586 0.78 MEN1 (0.41) NOTUMDDB1CRBN
SCHEMBL3003057 0.75 L3MBTL1 (0.40) NOTUMP2RX7
SCHEMBL3001942 0.75 HTR7 (0.44)
SCHEMBL2998001 0.74 HTR7 (0.41) DDB1CRBN
SCHEMBL2996862 0.74 MGLL (0.38) NOTUM
SCHEMBL3012380 0.71 HTR7 (0.46) NOTUMP2RX7
SCHEMBL3001198 0.69 ALDH1A1 (0.41) CRBN
SCHEMBL2998069 0.68 HTR2C (0.34) P2RX7DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544705-B2 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2009-06-09 US claimed
EP-1608655-B1 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS NIKEM RESEARCH SRL (IT) 2008-07-16 EP claimed
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2007-02-01 US claimed
US-20100173945-A1 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2010-07-08 US disclosed
US-20100173945-A1 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2010-07-08 US disclosed
US-20100173945-A1 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2010-07-08 US disclosed
US-7732473-B2 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof NEUROTUNE AG (CH) 2010-06-08 US disclosed
US-7732473-B2 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof NEUROTUNE AG (CH) 2010-06-08 US disclosed
US-7732473-B2 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof NEUROTUNE AG (CH) 2010-06-08 US disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
US-7544705-B2 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2009-06-09 US disclosed
US-7544705-B2 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2009-06-09 US disclosed
US-7544705-B2 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2009-06-09 US disclosed
EP-1608655-B1 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS NIKEM RESEARCH SRL (IT) 2008-07-16 EP disclosed
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2007-02-01 US disclosed
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2007-02-01 US disclosed
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173945-A1 Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof GRIN3B, GRIN3A, GRIN1 NOTUM 897/4885AR 1688/4885P2RX7 55/4885
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof OPRL1, GRIN3B, GRIN3A NOTUM 696/4885AR 2188/4885P2RX7 32/4885
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents GRIN3A, GRIN1, GRIN3B NOTUM 662/4885AR 3192/4885P2RX7 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.